Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Sections
Personal tools
Log in
 
You are here: Home › Publications › Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.

Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.

Meltzer SJ. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.. Oncogene .

Announcement